Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M2M
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Administration
- Oral
01
Overview
M2M is a non-hormonal ayurvedic menstrual modulator developed and marketed by Anglo-French Drugs & Industries. Formulated as an oral syrup and tablet, M2M acts as a uterine tonic, blood purifier, and fertility booster. It is indicated for the management of irregular menstrual cycles, amenorrhea (absence of periods), dysmenorrhea, polymenorrhea, dysfunctional uterine bleeding (DUB), and female infertility. M2M is reported to help regularize the menstrual cycle, control menorrhagia, relieve premenstrual syndrome (PMS), and induce ovulation to increase conception rates. Additionally, it possesses antioxidant, anti-inflammatory, antimicrobial, and metabolism-enhancing properties.
- Brand names
- M2MM-2MM 2MM2M SyrupM-2M SyrupM 2M SyrupM2M TabletM-2M TabletM 2M Tablet
Beyond the preview
Go deeper on M2M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M2M.